

Product datasheet for TG502824

Fbxw7 Mouse shRNA Plasmid (Locus ID 50754)

Product data:

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	Fbxw7 Mouse shRNA Plasmid (Locus ID 50754)
Locus ID:	50754
Synonyms:	1110001A17Rik; AGO; Cdc4; Fbw7; Fbwd6; Fbx30; Fbxo30; Fbxw6; SEL-10
Vector:	pGFP-V-RS (TR30007)
E. coli Selection:	Kanamycin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	Fbxw7 - Mouse, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 50754). 5μg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
RefSeq:	BC085184, BC131648, NM 001177773, NM 001177774, NM 080428, NM 001177773.1, NM 001177774.1, NM 080428.1, NM 080428.2, NM 080428.3, BC060620, BC065380, BC066093
UniProt ID:	<u>Q8VBV4</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

GRIGENE Fbxw7 Mouse shRNA Plasmid (Locus ID 50754) – TG502824

Summary:	Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:21953459, PubMed:22748924). Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination (PubMed:22748924). Mediates ubiquitination and subsequent degradation of CCNE1 and MYC (PubMed:22748924). Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NOTCH2, MCL1 and probably PSEN1 (By similarity). Acts as a negative regulator of JNK signaling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation (By similarity). SCF(FBXW7) complex mediates the ubiquitination and subsequent degradation of NFE2L1 (PubMed:21953459). Involved in bone homeostasis and negative regulation of osteoclast differentiation (PubMed:29149593). Regulates the
	amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination (PubMed:27238018).[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .
Performance Guaranteed:	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
	For non-conforming shRNA, requests for replacement product must be made within ninety

(90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US